Excess TGF-β mediates muscle weakness associated with bone metastases in mice

Nature Medicine

Volumn 21, Issue 11, 2015, Pages 1262-1271

  Waning, David L ^a   Mohammad, Khalid S ^a   Reiken, Steven ^b   Xie, Wenjun ^b   Andersson, Daniel C ^b,f   John, Sutha ^a   Chiechi, Antonella ^a   Wright, Laura E ^a   Umanskaya, Alisa ^b   Niewolna, Maria ^a   Trivedi, Trupti ^a   Charkhzarrin, Sahba ^a   Khatiwada, Pooja ^a   Wronska, Anetta ^b   Haynes, Ashley ^b   Benassi, Maria Serena ^c   Witzmann, Frank A ^a   Zhen, Gehua ^d   Wang, Xiao ^d   Cao, Xu ^d   Roodman, G David ^a,e   Marks, Andrew R ^b   Guise, Theresa A ^a   more..

^a INDIANA UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Richard L Roudebush VA Medical Center   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RYANODINE RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA; CALCIUM; MUSCLE PROTEIN; NOX4 PROTEIN, HUMAN; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RYANODINE RECEPTOR; RYANODINE RECEPTOR 1, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BONE DESTRUCTION; BONE MATRIX; BONE METASTASIS; BREAST CANCER CELL LINE; CONTROLLED STUDY; EXERCISE; FEMALE; GRIP STRENGTH; HEART LEFT VENTRICLE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG CANCER CELL LINE; METASTASIS; MOUSE; MUSCLE CONTRACTILITY; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; NONHUMAN; OSTEOLYSIS; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BONE TUMOR; BREAST TUMOR; CALCIUM SIGNALING; CAMURATI ENGELMANN DISEASE; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE MODEL; GENETICS; LUNG TUMOR; MALE; MCF-7 CELL LINE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MULTIPLE MYELOMA; NEOPLASM; NUDE MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHOTON ABSORPTIOMETRY; PROSTATE TUMOR; SCID MOUSE; SECONDARY; SKELETAL MUSCLE; TUMOR CELL LINE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CALCIUM; CALCIUM SIGNALING; CAMURATI-ENGELMANN SYNDROME; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MCF-7 CELLS; MICE; MICE, NUDE; MICE, SCID; MULTIPLE MYELOMA; MUSCLE CONTRACTION; MUSCLE PROTEINS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; NADPH OXIDASE; NEOPLASMS; OSTEOLYSIS; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; X-RAY MICROTOMOGRAPHY;

EID: 84946203483     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3961     Document Type: Article

References (54)

1. Fearon K.C., Glass D.J., & Guttridge D.C. Cancer cachexia: mediators, signaling and metabolic pathways. Cell Metab. 16, 153-166 (2012
2. Gentry B.A., Ferreira J.A., Phillips C.L., & Brown M. Hindlimb skeletal muscle function in myostatin-deficient mice. Muscle Nerve 43, 49-57 (2011
3. Mendias C.L., Marcin J.E., Calerdon D.R., & Faulkner J.A. Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J. Appl. Physiol. 101, 898-905 (2006
4. Weilbaecher K.N., Guise T.A., & McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411-425 (2011
5. Coleman R.E., et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat. Rev. 36, 615-620 (2010
6. Kang Y., et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA 102, 13909-13914 (2005
7. Korpal M., et al. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960-966 (2009
8. Tang Y., et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757-765 (2009
9. Zalk R., Lehnart S.E., & Marks A.R. Modulation of the ryanodine receptor and intracellular calcium. Annu. Rev. Biochem. 76, 367-385 (2007
10. Andersson D.C., et al. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14, 196-207 (2011
11. Guise T.A., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98, 1544-1549 (1996
12. Vera-Ramirez L., et al. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit. Rev. Oncol. Hematol. 80, 347-368 (2011
13. Bellinger A.M., et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15, 325-330 (2009
14. Lu X., & Kang Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc. Natl. Acad. Sci. USA 106, 9385-9390 (2009
15. Guise T.A., Yoneda T., Yates A.J., & Mundy G.R. The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-α enhance hypercalcemia in vivo and bone resorption in vitro. J. Clin. Endocrinol. Metab. 77, 40-45 (1993
16. Hjorth-Hansen H., et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J. Bone Miner. Res. 14, 256-263 (1999
17. Bellinger A.M., et al. Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity. Proc. Natl. Acad. Sci. USA 105, 2198-2202 (2008
18. Andersson D.C., & Marks A.R. Fixing ryanodine receptor Ca leak: a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov. Today Dis. Mech. 7, e151-e157 (2010
19. Dallas S.L., Rosser J.L., Mundy G.R., & Bonewald L.F. Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-β from bone matrix. J. Biol. Chem. 277, 21352-21360 (2002
20. Kang Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003
21. Yin J.J., et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999
22. Shi Y., & Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003
23. Dasch J.R., Pace D.R., Waegell W., Inenaga D., & Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor β2 affinity purification. J. Immunol. 142, 1536-1541 (1989
24. Biswas S., et al. Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS ONE 6, e27090 (2011
25. Sun Q.A., et al. Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4. Proc. Natl. Acad. Sci. USA 108, 16098-16103 (2011
26. Carmona-Cuenca I., et al. Upregulation of the NADPH oxidase NOX4 by TGF-β in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 49, 965-976 (2008
27. Hubackova S., Krejcikova K., Bartek J., & Hodny Z. IL1- and TGF-β-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced and drug-induced paracrine "bystander senescence". Aging (Albany NY) 4, 932-951 (2012
28. Michaeloudes C., Sukkar M.B., Khorasani N.M., Bhavsar P.K., & Chung K.F. TGF-β regulates Nox4, MnSOD and catalase expression and IL-6 release in airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 300, L295-L304 (2011
29. Yan F., et al. Nox4 and redox signaling mediate TGF-β-induced endothelial cell apoptosis and phenotypic switch. Cell Death Dis. 5, e1010 (2014
30. Jiang J.X., et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic. Biol. Med. 53, 289-296 (2012
31. Janssens K., et al. Mutations in the gene encoding the latency-associated peptide of TGF-β1 cause Camurati-Engelmann disease. Nat. Genet. 26, 273-275 (2000
32. Janssens K., ten Dijke P., Ralston S.H., Bergmann C., & Van Hul W. Transforming growth factor-β1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J. Biol. Chem. 278, 7718-7724 (2003
33. Mendias C.L., et al. Transforming growth factor-β induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 45, 55-59 (2012
34. Zhou X., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543 (2010
35. McPherron A.C., Lawler A.M., & Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387, 83-90 (1997
36. Bogdanovich S., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418-421 (2002
37. Wehrens X.H., et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304, 292-296 (2004
38. Dunn L.K., et al. Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 4, e6896 (2009
39. Soule H.D., Vazguez J., Long A., Albert S., & Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51, 1409-1416 (1973
40. Yin J.J., et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA 100, 10954-10959 (2003
41. Hu Z., et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum. Gene Ther. 23, 871-882 (2012
42. Johnson R.W., et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin. Exp. Metastasis 31, 945-959 (2014
43. Jackson N., et al. Two new IgA1-? plasma cell leukaemia cell lines (JJN-1, & JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin. Exp. Immunol. 75, 93-99 (1989
44. Bonetto A., Andersson D.C., & Waning D.L. Assessment of muscle mass and strength in mice. Bonekey Rep. 4, 732 (2015
45. Yamada T., et al. Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. Arthritis Rheum. 60, 3280-3289 (2009
46. Aydin J., et al. Increased mitochondrial Ca2+ and decreased sarcoplasmic reticulum Ca2+ in mitochondrial myopathy. Hum. Mol. Genet. 18, 278-288 (2009
47. Lai X., et al. Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteomics Clin. Appl. 2, 1140-1152 (2008
48. Keller A., Nesvizhskii A.I., Kolker E., & Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383-5392 (2002
49. Nesvizhskii A.I., Keller A., Kolker E., & Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646-4658 (2003
50. Lai X., Wang L., Tang H., & Witzmann F.A. A novel alignment method and multiple filters for exclusion of unqualified peptides to enhance label-free quantification using peptide intensity in LC-MS/MS. J. Proteome Res. 10, 4799-4812 (2011
51. Mohammad K.S., et al. Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 4, e5275 (2009
52. Kimura Y., Kurzydlowski K., Tada M., & MacLennan D.H. Phospholamban regulates the Ca2+-ATPase through intramembrane interactions. J. Biol. Chem. 271, 21726-21731 (1996
53. Cheng H., et al. Amplitude distribution of calcium sparks in confocal images: theory and studies with an automatic detection method. Biophys. J. 76, 606-617 (1999
54. de Winter J.C.F. Using the Student's t-test with extremely small sample sizes. Pract. Assess., Res. Eval. 18, 1-12 (2013